(2E,4E,6E,8E,10E,12E)-2,7,11-trimethyl-13-(2,6,6-trimethylcyclohex-1-en-1-yl)trideca-2,4,6,8,10,12-hexaenoic acid | 1053-30-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (2E,4E,6E,8E,10E,12E)-2,7,11-trimethyl-13-(2,6,6-trimethylcyclohex-1-en-1-yl)trideca-2,4,6,8,10,12-hexaenoic acid
• 英文别名: 12'-apo-β-caroten-12'-oic acid；12'-apo-β-carotenoic-12'-acid；β-12'-apo-carotenoic acid；12'-apo-β-carotenoic acid；12'-Apo-β-carotinsaeure-(12')；β-Apo-12'-carotinsaeure；(2E,4E,6E,8E,10E,12E)-2,7,11-trimethyl-13-(2,6,6-trimethylcyclohexen-1-yl)trideca-2,4,6,8,10,12-hexaenoic acid
• CAS: 1053-30-1
• 化学式: C₂₅H₃₄O₂
• 分子量: 366.544
• InChiKey: AQYCHKYBQMYQCM-UPFRCXMFSA-N

物化性质

• 熔点：
  184-185 °C
• 沸点：
  540.4±19.0 °C(Predicted)
• 密度：
  0.999±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  methyl (E)-4-bromo-2-methylbut-2-enoate 生成 (2E,4E,6E,8E,10E,12E)-2,7,11-trimethyl-13-(2,6,6-trimethylcyclohex-1-en-1-yl)trideca-2,4,6,8,10,12-hexaenoic acid
  参考文献：
  名称：

  Haeck,H.H.; Kralt,T., Recueil des Travaux Chimiques des Pays-Bas, 1968, vol. 87, p. 709 - 714

  摘要：

  DOI：

文献信息

• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• Synthesis of apocarotenoids by acyclic cross metathesis and characterization as substrates for human retinaldehyde dehydrogenases
  作者：Marta Domínguez、Raquel Pequerul、Rosana Alvarez、Joan Giménez-Dejoz、Eszter Birta、Sergio Porté、Ralph Rühl、Xavier Parés、Jaume Farrés、Angel R. de Lera

  DOI：10.1016/j.tet.2018.03.050

  日期：2018.5

  based on the acyclic cross-metathesis of the hexaene derived from retinal and the corresponding partners. These compounds can be enzymatically converted to their carboxylic acids by the human aldehyde dehydrogenases involved in retinaldehyde oxidation. Their kinetic parameters suggest that these enzymes might play a role in the physiological metabolism of apocarotenoids.

  基于己烯的无环交叉复分解，已经实现了三种合成类胡萝卜素的新合成，即14'-apo-β-胡萝卜素，12'-apo-β-胡萝卜素和10'-apo-β-胡萝卜素。来自视网膜和相应的伴侣。这些化合物可以通过参与视黄醛氧化的人醛脱氢酶酶促转化为它们的羧酸。它们的动力学参数表明这些酶可能在类胡萝卜素的生理代谢中起作用。
• Glucuronidated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014734A1

  公开（公告）日：2007-01-18

  This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol and/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also provides methods of treating and/or preventing vascular diseases, by administering at least one glucuronidated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one glucuronidated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  这项发明提供了葡萄糖醛酸化的尼布ivolol代谢物以及用于治疗心血管疾病的葡萄糖醛酸化的尼布ivolol代谢物的制药组合物。此外，该发明还提供了包含尼布ivolol和/或至少一种尼布ivolol的葡萄糖醛酸化代谢物和/或至少一种其他活性化合物的药用可接受载体的组合物。该发明还提供了通过向受影响血管疾病的靶位点投与至少一种能释放治疗有效量一氧化氮的尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防血管疾病的方法。此外，该发明旨在通过投与至少一种尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防偏头痛。该发明还可与代谢综合征紊乱的单一治疗或联合治疗一起使用。
• HYDROXYLATED NEBIVOLOL METABOLITES
  申请人：O'Donnell John P.

  公开号：US20110065783A1

  公开（公告）日：2011-03-17

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化的内比洛尔代谢物在急性给药后以浓度依赖的方式增加人类内皮细胞制备的一氧化氮释放。此外，羟基化的内比洛尔代谢物，包括但不限于4-羟基-6,6′-二氟-、4-羟基-5-酚-6,6′-二氟-和4-羟基-8-苯基-6,6′-二氟-，具有在慢性给药后增加人类内皮细胞释放一氧化氮能力的能力。本发明提供了羟基化的内比洛尔代谢物和包含内比洛尔和/或至少一种内比洛尔羟基化代谢物和/或至少一种用于治疗心血管疾病的其他化合物或其药学上可接受的盐的组合物。此外，本发明提供了通过给靶向受影响的血管疾病的部位至少给予一种能够释放治疗有效量一氧化氮的内比洛尔羟基化代谢物的方法来治疗和/或预防血管疾病的方法。此外，本发明还涉及通过至少给予一种内比洛尔羟基化代谢物来治疗和/或预防偏头痛。此发明还可与代谢综合征疾病的单个治疗或联合治疗一起使用。
• Derivatives of Alpha-alkyl polyolefinic compounds useful in the treatment of psoriasis
  申请人：USV PHARMACEUTICAL CORPORATION

  公开号：EP0137155A2

  公开（公告）日：1985-04-17

  The present invention relates to novel a-alkyl polyolefinic compounds and to pharmaceuticals containing said compounds. The pharmaceuticals are useful for the treatment of psoriasis. The a-alkyl polyolefinic compounds have the structure wherein n is 0 to 3; R, and R4 are each independently hydrogen or an alkyl group of from 1 to 5 carbon atoms; R2 is an alkyl group of from 1 to 5 carbon atoms; R3 is H, C1-C5 alkyl, cyclo C3-C7 alkyl, C2-C5 alkenyl, cyclo C3-C7 alkenyl, aryl, hydroxy, C1-C5 alkoxy, aryloxy, arylalkoxy, formyl, C1-C6 alkylcarbonyl, C2-C5 alkenylcarbonyl, arylcarbonyl, aryl C1-C5 alkylcarbonyl, aryl C2-C5 alkenylcarbonyl, NR6R5, SR5, retinyloxy, retinoyl, retinoyloxy, or R6 is H, C1-C20 alkyl, aryl, aralkyl; and Z is a cycloalkyl, cycloalkenyl or cycloalkadienyl group substituted with from 0 to 5 alkyl groups, a keto group or a hydroxyl group, or a phenyl group substituted with from 0 to 4 hydroxy, alkoxy, alkyl or trifluoromethyl groups or halogen atoms or combinations thereof; and the pharmaceutically- acceptable salts thereof.

  本发明涉及新型 a-烷基聚烯烃化合物和含有上述化合物的药物。这些药物可用于治疗牛皮癣。a- 烷基聚烯烃化合物具有如下结构 其中 n 为 0 至 3； R 和 R4 各自独立地为氢或 1 至 5 个碳原子的烷基； R2 是 1 至 5 个碳原子的烷基； R3是H、C1-C5烷基、环C3-C7烷基、C2-C5烯基、环C3-C7烯基、芳基、羟基、C1-C5烷氧基、芳氧基、芳烷氧基、甲酰基、C1-C6烷基羰基、C2-C5烯基羰基、芳基羰基、芳基C1-C5烷基羰基、芳基C2-C5烯基羰基、NR6R5、SR5、 视黄氧基、视黄酰基、视黄酰氧基，或 R6 是 H、C1-C20 烷基、芳基、芳烷基；和 Z 是被 0 至 5 个烷基、酮基或羟基取代的环烷基、环烯基或环烷二烯基，或被 0 至 4 个羟基、烷氧基、烷基或三氟甲基或卤原子或其组合取代的苯基；及其药学上可接受的盐。